MCID: ANV001
MIFTS: 46

Anovulation

Categories: Endocrine diseases, Reproductive diseases

Aliases & Classifications for Anovulation

MalaCards integrated aliases for Anovulation:

Name: Anovulation 12 54 44 15 70

Classifications:



External Ids:

Disease Ontology 12 DOID:3781
MeSH 44 D000858
NCIt 50 C34388
SNOMED-CT 67 34571000
UMLS 70 C0003128

Summaries for Anovulation

Disease Ontology : 12 An ovarian disease that is characterized by the absence of ovulation.

MalaCards based summary : Anovulation is related to hyperprolactinemia and galactorrhea. An important gene associated with Anovulation is SHBG (Sex Hormone Binding Globulin), and among its related pathways/superpathways are Peptide ligand-binding receptors and Prolactin Signaling Pathway. The drugs Polyestradiol phosphate and Estradiol have been mentioned in the context of this disorder. Affiliated tissues include ovary, pituitary and breast, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Wikipedia : 73 Anovulation is when the ovaries do not release an oocyte during a menstrual cycle. Therefore, ovulation... more...

Related Diseases for Anovulation

Diseases related to Anovulation via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 270)
# Related Disease Score Top Affiliating Genes
1 hyperprolactinemia 30.9 SHBG PRL INS IGF1 GNRH1
2 galactorrhea 30.9 PRL IGF1
3 ovarian cyst 30.6 PRL GNRH1 CYP19A1
4 ovarian hyperstimulation syndrome 30.3 SHBG INS GNRH1 FSHR FSHB CYP19A1
5 precocious puberty 30.3 GNRH1 FSHR CYP21A2
6 polycystic ovary syndrome 30.2 SRD5A1 SHBG PRL LEP INS IGFBP1
7 lipoid congenital adrenal hyperplasia 30.2 SRD5A1 GNRH1 CYP21A2 CYP19A1
8 pituitary gland disease 30.2 PRL INS IGF1 GNRH1 CRH CGA
9 pituitary adenoma 30.2 PRL IGF1 GNRH1 CRH
10 diabetes insipidus 30.1 PRL INS CRH
11 empty sella syndrome 30.1 PRL INS IGF1 GNRH1
12 pituitary adenoma, prolactin-secreting 30.1 PRL IGF1 GNRH1
13 placenta disease 30.1 INS CRP CGA
14 hypothalamic disease 30.1 PRL INS GNRH1 CRH
15 hypogonadism 30.0 SHBG PRL LEP INS IGF1 GNRH1
16 vaginal discharge 30.0 HP GNRH1 CYP19A1 CRP
17 insulin-like growth factor i 30.0 SHBG PRL LEP INS IGFBP1 IGF1
18 uremia 29.9 LEP INS CRP
19 alopecia 29.9 SRD5A1 SHBG PRL IGF1
20 hyperinsulinism 29.9 SHBG LEP INS IGFBP1 IGF1 GNRH1
21 hyperandrogenism 29.9 SRD5A1 SHBG PRL INS IGFBP1 IGF1
22 lipid metabolism disorder 29.9 SHBG LEP INS CYP21A2 CRP
23 adenoma 29.9 PRL IGF1 CYP21A2 CRH
24 acne 29.9 SRD5A1 SHBG PRL INS IGF1 CYP21A2
25 acanthosis nigricans 29.8 SHBG PRL LEP INS IGF1
26 bone resorption disease 29.8 LEP INS IGF1 CYP19A1 CRP
27 infertility 29.7 SHBG PRL LEP INS IGFBP1 GNRH1
28 amenorrhea 29.7 SHBG PRL LEP INS IGF1 GNRH1
29 hyperglycemia 29.7 LEP INS IGF1 GHRL
30 gestational diabetes 29.7 SHBG LEP INS IGFBP1 CRP
31 androgenic alopecia 29.6 SRD5A1 SHBG PRL INS IGF1 CYP19A1
32 hypogonadotropic hypogonadism 29.6 SHBG PRL LEP INS GNRH1 FSHB
33 ovarian disease 29.3 SHBG PRL LEP INS IGFBP1 IGF1
34 anorexia nervosa 29.3 SHBG PRL LEP INS IGFBP1 IGF1
35 hypothyroidism 29.2 SHBG PRL LEP INS IGF1 GNRH1
36 glucose intolerance 29.1 SHBG PRL LEP INS IGFBP1 IGF1
37 type 2 diabetes mellitus 28.5 SHBG PRL LEP INS IGFBP1 IGF1
38 polycystic ovary syndrome 1 11.0
39 diffuse peritoneal leiomyomatosis 10.4 GNRH1 CYP19A1
40 postmenopausal atrophic vaginitis 10.4 SHBG GNRH1
41 secondary adrenal insufficiency 10.4 INS IGF1
42 malignant otitis externa 10.4 INS CRP
43 otitis externa 10.4 INS CRP
44 uvulitis 10.4 INS CRP
45 pineal hyperplasia, insulin-resistant diabetes mellitus, and somatic abnormalities 10.4 INS IGF1
46 hypoactive sexual desire disorder 10.4 SHBG CYP19A1
47 cavernous sinus thrombosis 10.4 INS CRP
48 pelvic varices 10.4 SHBG PRL GNRH1
49 hermaphroditism 10.4 SHBG CGA AMHR2
50 oocyte maturation defect 1 10.4 CYP19A1 CGA BMP15

Graphical network of the top 20 diseases related to Anovulation:



Diseases related to Anovulation

Symptoms & Phenotypes for Anovulation

GenomeRNAi Phenotypes related to Anovulation according to GeneCards Suite gene sharing:

26 (show all 20)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-102 9.89 IGF1
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-104 9.89 IGF1
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-132 9.89 BMP15
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-134 9.89 IGF1
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-138 9.89 BMP15
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-144 9.89 IGF1
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-153 9.89 IGF1
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-19 9.89 BMP15
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-20 9.89 BMP15
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-200 9.89 IGF1
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-21 9.89 IGF1
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-213 9.89 BMP15 IGF1 SHBG
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-34 9.89 IGF1
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-69 9.89 SHBG
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-84 9.89 IGF1
16 Decreased viability GR00221-A-1 9.4 AMHR2
17 Decreased viability GR00221-A-2 9.4 AMHR2
18 Decreased viability GR00249-S 9.4 AMHR2 CGA FSHB GHRL HP SRD5A1
19 Decreased viability GR00386-A-1 9.4 BMP15 CGA SRD5A1
20 Decreased viability GR00402-S-2 9.4 CGA

MGI Mouse Phenotypes related to Anovulation:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.28 AMHR2 BMP15 CGA CRH CYP19A1 FSHB
2 homeostasis/metabolism MP:0005376 10.28 AMHR2 CGA CRH CRP CYP19A1 FSHB
3 immune system MP:0005387 10.21 AMHR2 CRH CRP CYP19A1 CYP21A2 FSHR
4 integument MP:0010771 10.06 AMHR2 CRH CYP19A1 CYP21A2 FSHR GNRH1
5 liver/biliary system MP:0005370 9.86 CRH CYP19A1 GNRH1 HP IGFBP1 INS
6 neoplasm MP:0002006 9.76 AMHR2 FSHR GNRH1 HP IGF1 LEP
7 renal/urinary system MP:0005367 9.56 AMHR2 CRH CYP19A1 GNRH1 HP IGF1
8 reproductive system MP:0005389 9.4 AMHR2 BMP15 CGA CYP19A1 FSHB FSHR

Drugs & Therapeutics for Anovulation

Drugs for Anovulation (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 105)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Polyestradiol phosphate Approved Phase 4 28014-46-2
2
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
3
Sodium citrate Approved, Investigational Phase 4 68-04-2
4
Levoleucovorin Approved, Investigational Phase 4 68538-85-2 149436
5
Metformin Approved Phase 4 657-24-9 14219 4091
6
Menotropins Approved Phase 4 9002-68-0, 61489-71-2 5360545
7
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
8
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
9
Enclomiphene Investigational Phase 4 15690-57-0
10 Contraceptive Agents Phase 4
11 Estradiol 17 beta-cypionate Phase 4
12 Estradiol 3-benzoate Phase 4
13 Calcium, Dietary Phase 4
14 Chelating Agents Phase 4
15 Anticoagulants Phase 4
16 Citrate Phase 4
17 Estrogen Receptor Antagonists Phase 4
18 Estrogen Antagonists Phase 4
19 Clomiphene Phase 4
20 Estrogens Phase 4
21 Zuclomiphene Phase 4
22 Estrogen Receptor Modulators Phase 4
23 Hypoglycemic Agents Phase 4
24 Pharmaceutical Solutions Phase 4
25 Hormone Antagonists Phase 4
26 Hormones Phase 4
27 Follicle Stimulating Hormone Phase 4
28 Chorionic Gonadotropin Phase 4
29
Calcium Nutraceutical Phase 4 7440-70-2 271
30
Desogestrel Approved Phase 3 54024-22-5 40973
31
Medroxyprogesterone acetate Approved, Investigational Phase 3 71-58-9
32
Progesterone Approved, Vet_approved Phase 3 57-83-0 5994
33 Contraceptives, Oral Phase 3
34 Contraceptive Agents, Male Phase 3
35 Aromatase Inhibitors Phase 3
36 Tin Fluorides Phase 3
37
Medroxyprogesterone Phase 3 520-85-4 10631
38 Progestins Phase 3
39
Anastrozole Approved, Investigational Phase 2 120511-73-1 2187
40
Inositol Approved, Investigational, Withdrawn Phase 2 87-89-8
41
Flutamide Approved, Investigational Phase 2 13311-84-7 3397
42
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
43
Inulin Approved, Investigational, Nutraceutical Phase 2 9005-80-5 24763
44 Vasodilator Agents Phase 2
45 Phosphodiesterase Inhibitors Phase 2
46 Sildenafil Citrate Phase 2 171599-83-0
47 Phosphodiesterase 5 Inhibitors Phase 2
48 Antineoplastic Agents, Hormonal Phase 2
49 Trace Elements Phase 2
50 Nutrients Phase 2

Interventional clinical trials:

(show top 50) (show all 60)
# Name Status NCT ID Phase Drugs
1 Administration of Single High Dose Letrozole for Ovulation Induction - A Randomized Controlled Trial Unknown status NCT02703649 Phase 4 Letrozole
2 Endometrial Thickness And Subendometrial Vascularity In Anovulatory Polycystic Ovarian Syndrome Patients Treated by Metformin Unknown status NCT03486626 Phase 4 Metformin
3 Comparison of Three Different Strategies for Treating Infertility in Anovulatory Women With Polycystic Ovary Syndrome: a Multicentre Randomized Controlled Clinical Trial Unknown status NCT00461643 Phase 4 Clomiphene citrate, metformin, metformin plus clomiphene citrate, gonadotropins
4 Concomitant Clomiphene Citrate and Estradiol Versus Clomiphene Citrate Alone in Ovulation Induction: a Randomized Controlled Trial Unknown status NCT02186782 Phase 4 Clomiphene citrate and Estradiol;Clomiphene citrate and Placebo
5 Double Blind Cross-over Randomized Controlled Trial Comparing Letrozole Versus Clomifene Citrate for Ovulation Induction in Women With Polycystic Ovarian Syndrome Completed NCT00478504 Phase 4 Letrozole;Clomifene citrate
6 Clomiphene Citrate Versus Metformin as First-Line Approach for the Treatment of Anovulation in Infertile Patients With Polycystic Ovary Syndrome Completed NCT00471523 Phase 4 Clomiphene citrate;Metformin
7 Gonadotrophin Dosage Using a Threshold Nomogram for Ovulation Induction in WHO Group II Anovulatory Infertility Completed NCT01250821 Phase 4 Menopur
8 Laparoscopic Ovarian Diathermy or Metformin Plus Clomiphene Citrate Administration as Second-Line Treatment for Infertile Anovulatory Patients With Polycystic Ovary Syndrome: a Randomized Controlled Trial Completed NCT00558077 Phase 4 Metformin plus clomiphene citrate
9 Does Short-term Structured Exercise Training Program Plus Diet Intervention Improve Ovarian Sensitivity to Clomiphene Citrate in Polycystic Ovary Syndrome Patients (PCOS)? A Prospective Randomized Controlled Study Completed NCT01004068 Phase 4 Clomiphene citrate
10 Effects of Metformin With or Without Folate Supplementation on Homocysteine Levels and Endothelium in Women With Polycystic Ovary Syndrome Completed NCT00953355 Phase 4 Folate plus metformin;Placebo plus metformin
11 Effects of Structured Exercise Program Versus Hypocaloric Hyperproteic Diet on the Reproductive Function in Obese Anovulatory Infertile Patients With Polycystic Ovary Syndrome: a 24-Week Prospective Study. Completed NCT00473538 Phase 4
12 Ovarian Function in Women With Polycystic Ovary Syndrome Recruiting NCT03252223 Phase 4 Recombinant Follicle Stimulating Hormone
13 Can Hormonal Effects of the Oral Gonadotropin Releasing Hormone (GnRH) Antagonist Withstand When Administered at Different Points in the Menstrual Cycle? Not yet recruiting NCT04060992 Phase 4 Elagolix 200 MG Oral Tablet [Orilissa]
14 Pilot Study: Role of Dietary Fiber in PCOS Anovulation Terminated NCT00703092 Phase 4 Fiber-Stat
15 A Multi-Centre, Two-Arm, Interventional, Phase IV Study to Evaluate Tailoring of Recombinant FSH Treatment in Subjects With Chronic Anovulation Using the Gonal-f® Prefilled Pen in Women Undergoing Ovulation Induction Terminated NCT01871532 Phase 4 Gonal-f®
16 The Effectiveness of Cyclic Desogestrel Therapy for Abnormal Uterine Bleeding Associated With Anovulation: a Non-inferiority Double Blinded Randomized Control Trial Unknown status NCT02103764 Phase 3 Desogestrel;Medroxyprogesterone acetate
17 Open-Label, Parallel-Group, Randomized, Multicenter Phase III Trial to Compare the Efficacy and Safety of a 250 mcg SC Dose of MSJ-0011 to a 5,000 IU IM Dose of Urinary Human Chorionic Gonadotropin in Inducing Ovulation in Japanese Women Diagnosed With Anovulation or Oligo-Ovulation Secondary to Hypothalamic-Pituitary Dysfunction or Polycystic Ovarian Syndrome, and Who Are Undergoing Ovulation Induction With Follitropin Alfa Completed NCT01653743 Phase 3 MSJ-0011;urinary hCG (u-hCG);Follitropin alpha
18 Phase III Clinical Study of Domestic Recombinant Human Follitropin for Injection to Treat WHO Class II Anovulation Completed NCT02335879 Phase 3
19 A Phase III Clinical Study for the Comparison Evaluation of DA-3801 and Gonal-F® in Infertile Female Patients With Chronic Anovulation Syndrome Completed NCT01820728 Phase 3 DA-3801 Injection;Gonal-F®
20 A Randomized, Assessor-blinded, Parallel Group, Multi-center, Non-inferiority Study Investigating the Efficacy and Safety of Highly Purified Urofollitropin for Injection Compared to Recombinant Human Follitropin Alfa for Injection for Ovulation Induction Using a Low-dose, Step-up Protocol in Chinese Females With WHO Group II Anovulatory Infertility Failing to Conceive on Clomiphene Citrate Completed NCT01923194 Phase 3 Highly Purified Urofollitropin;Recombinant Human Follitropin Alfa
21 Intrauterine Infusion of Autologous Platelet-rich Plasma to Prevent a Thin Endometrium in Infertile Women Undergoing Clomiphene Citrate Therapy: a Pilot Prospective Self-controlled Trial Completed NCT03770026 Phase 2, Phase 3 clomiphene citrate;Saline cervical flushing
22 An Open, Randomized, Parallel-Group, Multicentric, Comparative Study of Letrozole With Clomiphene Citrate for Induction of Ovulation in Anovulatory Infertility. Completed NCT00610077 Phase 3 Letrozole;Clomiphene citrate
23 Traditional Clomiphene Citrate Administration Versus a Stair-Step Approach: A Randomized Controlled Trial Completed NCT01008319 Phase 3 clomiphene citrate;clomiphene citrate
24 The Effect of Metformin Added to Clomiphene Citrate on Pregnancy Rates in Hyperandrogenic, Chronic Oligoovulatory or Anovulatory Women: A Randomized Trial Completed NCT00413179 Phase 3 Metformin;Clomiphene citrate;Placebo
25 Letrozole Versus Clomiphene Citrate for Ovulation Induction in Women With Polycystic Ovary Syndrome Unknown status NCT02551367 Phase 2 Letrozole;Clomiphene citrate;hcg hormone
26 Effectiveness and Safety of Bushen Culuan Decoction for Anovulatory Infertility:A Clinical Research of "Same Treatment for Different Diseases" Unknown status NCT03709849 Phase 2 experimental group: Bushen Culuan Decoction and Clomiphene Citrate Tablets placebo;control group: Clomiphene Citrate Tablets and Bushen Culuan Decoction placebo
27 Comparison of Micro-dose Human Chorionic Gonadotropin (hCG) With HMG in PCOs Patients With Previous Clomiphene Citrate (CC)-Resistant Anovulation Completed NCT00947713 Phase 1, Phase 2 low dose human chorionic gonadotropin;Clomiphen citrate plus HMG
28 A Phase II, Prospective, Randomized, Double-Blind, Multicenter, Dose Finding, Comparative Study for the Evaluation of the Aromatase Inhibitor Anastrozole (Multiple-Dose) Versus Clomiphene Citrate in Stimulating Follicular Growth and Ovulation in Infertile Women With Ovulatory Dysfunction Completed NCT00213148 Phase 2 Anastrozole 1 mg;Anastrozole 5 mg;Anastrozole 10 mg;Clomiphene Citrate 50 mg;Clomiphene Citrate 100 mg
29 The Effect of Sildenafil Citrate on the Success Rate of Ovulation Induction Using Clomiphene: A Randomized Controlled Trial. Completed NCT02663830 Phase 2 Sildenafil & clomiphene citrate;clomiphene only
30 Androgen Excess as a Cause for Adipogenic Dysfunction in PCOS Women Recruiting NCT01889199 Phase 2 Flutamide
31 Inositol Supplementation to Treat Polycystic Ovary Syndrome: A Double Blind Dose Ranging RCT (INSUPP-PCOS) Recruiting NCT03864068 Phase 2 Inositol
32 Influence of Pharmacogenetic Factors, Paroxetine and Clarithromycin on Pharmacokinetics of Clomiphene Completed NCT01289756 Phase 1 Clomiphene;clomiphene and paroxetine;clomiphene and clarithromycin
33 The Effects of Myo-inositol Plus Alpha-lactalbumin in Ovulation Induction of PCOS Myo-inositol-resistant Patients Unknown status NCT03667443
34 Whole Genome Analysis for the Detection of Key Genes in the Polycystic Ovary Syndrome - a Study on Multigenerational Families Unknown status NCT00665171
35 Clinical Advantages of Performing Concomitant Office Hysteroscopy and Endometrial Biopsy in Patients With Oligomenorrhea Seeking Infertility Treatment as Compared to Only Endometrial Biopsy: A Prospective Randomized Study Unknown status NCT03545945
36 The Cycle Disturbances, OLigomenorrhea and Amenorrhea (COLA) Study & Biobank Unknown status NCT02309047
37 Effect of Sildenafil Vaginal Gel Co-treatment With Clomiphene Citrate on Endometrial Thickness in Infertile Women With Prior Clomiphene Citrate Failure Due to Thin Endometrium: a Prospective Self-controlled Clinical Trial Completed NCT02710981 clomiphene citrate;Sildenafil vaginal gel
38 Transvaginal Ultrasound-Guided Ovarian Interstitial Laser Treatment in Anovulatory Women With Polycystic Ovarian Syndrome: A Randomized Prospective Study on the Effect of Laser Dose Used on the Outcome Completed NCT00643708
39 Improved Effects of Myo-inositol in Association With Alpha-lactalbumin in PCOS Women Completed NCT03422289
40 Clinical Investigation of the OV-Watch™ Personal Fertility Monitor for Women Undergoing Ovulation Induction With Clomiphene Citrate. Completed NCT00239603
41 N-acetyl Cysteine Plus Clomiphene Citrate Versus Metformin and Clomiphene Citrate in Treatment of Clomiphene-resistant Polycystic Ovary Syndrome Completed NCT01008046 combined N-acetyl cysteine -CC;combined metformin-CC
42 Dynamic Changes in the Serum Anti-Müllerian Hormone Level During Low-Dose recFSH Administration Further Support Its Role in the Anovulation of Polycystic Ovary Syndrome Completed NCT00492882 usual administration of exogenous recombinant FSH
43 Protocol for Drug Use Investigation of Follistim Injection Completed NCT00920634 Follitropin beta
44 Effect of Amlodipine and Clomid on Blood Flow of Preovulatory Follicle in Polycystic Ovarian Patients Completed NCT02544776 Clomifene citrate ( clomid 50 mg );Amlodipine
45 Visceral Fat Area and Other Predictors of Ovarian Response During Clomiphene Citrate Ovulation Induction in Patients With Polycystic Ovary Syndrome Completed NCT02269306 clomiphen citrate
46 A Randomised Controlled Clinical Trial of Metformin Versus Orlistat for the Management of Obese Anovulatory Women. Completed NCT00292799 Orlistat Vs Metformin
47 The Effect of Weight Reduction Surgery on Ovarian Function in Obese Anovulatory Patients Completed NCT00292773
48 Dietary Energy Requirements in Physically Active Men and Women, Objective 4B: Effects of Gynecological Age on LH Sensitivity to Energy Availability Completed NCT00260286
49 Effect of Bright Light on Sex Hormones and Ovulation in Humans Completed NCT00327366
50 Circulating Androgen Levels Are Not Affected by the Administration of Vaginal Micronized Progesterone for Withdrawal Bleeding in Patients With Polycystic Ovarian Syndrome Completed NCT03088046 Micronized Progesterone

Search NIH Clinical Center for Anovulation

Cochrane evidence based reviews: anovulation

Genetic Tests for Anovulation

Anatomical Context for Anovulation

MalaCards organs/tissues related to Anovulation:

40
Ovary, Pituitary, Breast, Bone, Kidney, Endothelial, Hypothalamus

Publications for Anovulation

Articles related to Anovulation:

(show top 50) (show all 2707)
# Title Authors PMID Year
1
Decreased active, total and altered active to total ghrelin ratio in normal weight women with the more severe form of polycystic ovary syndrome. 54 61
20096985 2010
2
Different phenotypes of polycystic ovary syndrome by Rotterdam criteria are differently steroidogenic but similarly insulin resistant. 61 54
19782351 2010
3
Apoptotic markers indicate nonalcoholic steatohepatitis in polycystic ovary syndrome. 61 54
19906783 2010
4
Large effects on body mass index and insulin resistance of fat mass and obesity associated gene (FTO) variants in patients with polycystic ovary syndrome (PCOS). 54 61
20092643 2010
5
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. 61 54
20091537 2010
6
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. 54 61
19821299 2009
7
Selective impairment in glycogen synthase kinase-3 and mitogen-activated protein kinase phosphorylation: comparisons with the hyperandrogenic and the hyperinsulinemic rats. 54 61
19027112 2009
8
A unique rodent model of cardiometabolic risk associated with the metabolic syndrome and polycystic ovary syndrome. 61 54
19470707 2009
9
WITHDRAWN: Insulin-sensitising drugs for polycystic ovary syndrome. 61 54
19588338 2009
10
Androgen circle of polycystic ovary syndrome. 54 61
19279033 2009
11
The effect of pharmaceutical intervention on lipid profile in polycystic ovary syndrome. 61 54
19413702 2009
12
Drug treatments for polycystic ovary syndrome. 54 61
19405411 2009
13
Oligo-ovulation or anovulation and hyperandrogenemia contribute to the decreased serum adiponectin levels in normal-weight women with PCOS with obesity and insulin resistance. 54 61
19243758 2009
14
Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. 61 54
19370625 2009
15
Transcriptional profiling with a pathway-oriented analysis identifies dysregulated molecular phenotypes in the endometrium of patients with polycystic ovary syndrome. 54 61
19141577 2009
16
Polycystic ovary syndrome in the adolescent. 61 54
19344852 2009
17
PCOS and cancer risk. 61 54
20067879 2009
18
Hyperreninemia characterizing women with polycystic ovary syndrome improves after metformin therapy. 54 61
19212122 2009
19
Pancreatic beta-cells dysfunction in polycystic ovary syndrome. 61 54
19078872 2008
20
Exercise training improves autonomic function and inflammatory pattern in women with polycystic ovary syndrome (PCOS). 54 61
18505468 2008
21
Cardiovascular risk in women with polycystic ovary syndrome. 54 61
18799960 2008
22
Cardiometabolic abnormalities in the polycystic ovary syndrome: pharmacotherapeutic insights. 61 54
18602948 2008
23
What every physician should know about polycystic ovary syndrome. 61 54
18844713 2008
24
Body shape and size and insulin resistance as early clinical predictors of hyperandrogenic anovulation in ethnic minority adolescent girls. 54 61
18639784 2008
25
Ovulation triggers in anovulatory women undergoing ovulation induction. 61 54
18646175 2008
26
The role of mullerian inhibiting substance in female reproduction. 61 54
18460940 2008
27
Does polycystic ovary syndrome start in childhood? 54 61
18552753 2008
28
Differences in low-grade chronic inflammation and insulin resistance in women with previous gestational diabetes mellitus and women with polycystic ovary syndrome. 54 61
18382906 2008
29
A case of Cushing's syndrome presenting as endometrial hyperplasia. 61 54
18363281 2008
30
Structural evaluation of type 3 dopaminergic receptor gene (DRD3) in chronic anovulatory women. 54 61
18393218 2008
31
Polycystic ovary syndrome in the Indian Subcontinent. 54 61
18181079 2008
32
HMG-CoA reductase inhibitors: do they have potential in the treatment of polycystic ovary syndrome? 61 54
18729532 2008
33
Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistance. 61 54
17984248 2007
34
Expression of leptin long-form receptor mRNA in luteinized granulosa cells of obese women with polycystic ovary syndrome. 61 54
17828512 2007
35
[Mechanism of action of insulin sensitizer agents in the treatment of polycystic ovarian syndrome]. 54 61
17547089 2007
36
Current approaches to the diagnosis and treatment of polycystic ovarian syndrome in youth. 54 61
17426408 2007
37
Is metformin a primary ovulatory agent in patients with polycystic ovary syndrome? 54 61
17145645 2006
38
Infertility in polycystic ovary syndrome: focus on low-dose gonadotropin treatment. 54 61
17185789 2006
39
Up-regulation of the phosphatidylinositol 3-kinase/protein kinase B pathway in the ovary of rats by chronic treatment with hCG and insulin. 54 61
16899578 2006
40
The frequency of insulin resistance calculated upon the basis of a fasting glucose to insulin ratio and characteristics of insulin resistant women with polycystic ovary syndrome. 54 61
16985482 2006
41
Review: fetal programming of polycystic ovary syndrome by androgen excess: evidence from experimental, clinical, and genetic association studies. 61 54
16522691 2006
42
Metabolic effects of obesity on reproduction. 61 54
16790096 2006
43
Contributions of androgen and estrogen to fetal programming of ovarian dysfunction. 54 61
16606451 2006
44
Increased circulating levels of matrix metalloproteinase-2 and -9 in women with the polycystic ovary syndrome. 54 61
16338908 2006
45
Effect of leptin administration on ovulation in food-restricted rhesus monkeys. 61 54
17106186 2006
46
Identification of a functional polymorphism of the human type 5 17beta-hydroxysteroid dehydrogenase gene associated with polycystic ovary syndrome. 61 54
16263811 2006
47
Polycystic ovary syndrome: the influence of environmental and genetic factors. 54 61
16728382 2006
48
Polycystic ovarian syndrome in Hong Kong Chinese women: patient characteristics and diagnostic criteria. 61 54
16219952 2005
49
[Polycystic ovary syndrome associated neoplasms]. 54 61
16444364 2005
50
Comparative study of plasma ghrelin levels in women with polycystic ovary syndrome, in hyperandrogenic women and in normal controls. 61 54
15890737 2005

Variations for Anovulation

Expression for Anovulation

Search GEO for disease gene expression data for Anovulation.

Pathways for Anovulation

Pathways related to Anovulation according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.41 PRL LEP GNRH1 GHRL FSHR FSHB
2
Show member pathways
12.3 PRL LEP INS CGA
3 12.15 GHRL FSHR FSHB CGA
4
Show member pathways
12.06 IGF1 GNRH1 FSHB CGA
5
Show member pathways
11.99 LEP INS IGF1 GHRL FSHB CGA
6 11.87 FSHR FSHB CRH CGA
7 11.69 LEP INS IGF1
8
Show member pathways
11.57 SRD5A1 CYP21A2 CYP19A1 CGA
9
Show member pathways
11.5 SRD5A1 CYP21A2 CYP19A1
10 11.33 PRL LEP INS
11 11.26 IGF1 CYP19A1 CGA
12 11.05 FSHR FSHB CYP19A1 CGA
13 10.87 INS IGF1 FSHR FSHB CYP19A1 CGA
14 10.76 PRL LEP INS GHRL
15 10.37 GNRH1 FSHR FSHB CGA

GO Terms for Anovulation

Cellular components related to Anovulation according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.83 SHBG PRL LOX LEP INS IGFBP1
2 extracellular space GO:0005615 9.47 PRL LOX LEP INS IGFBP1 IGF1
3 follicle-stimulating hormone complex GO:0016914 9.16 FSHB CGA

Biological processes related to Anovulation according to GeneCards Suite gene sharing:

(show all 32)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.24 PRL LEP INS IGFBP1 IGF1 GNRH1
2 G protein-coupled receptor signaling pathway GO:0007186 10.17 INS GNRH1 GHRL FSHR FSHB CRH
3 positive regulation of gene expression GO:0010628 10.04 INS IGF1 FSHB CRP CRH
4 positive regulation of cell migration GO:0030335 9.95 INS IGF1 FSHB CGA
5 response to nutrient levels GO:0031667 9.81 PRL LEP GHRL
6 regulation of protein phosphorylation GO:0001932 9.79 LOX LEP FSHR
7 steroid biosynthetic process GO:0006694 9.79 SRD5A1 CYP21A2 CYP19A1
8 response to estrogen GO:0043627 9.78 SRD5A1 GHRL CRH
9 glucose metabolic process GO:0006006 9.77 LEP INS GHRL
10 hormone-mediated signaling pathway GO:0009755 9.75 GHRL FSHR FSHB
11 regulation of osteoclast differentiation GO:0045670 9.65 FSHR FSHB
12 hypothalamus development GO:0021854 9.65 SRD5A1 CRH
13 ovarian follicle development GO:0001541 9.65 FSHR FSHB BMP15
14 adult feeding behavior GO:0008343 9.63 LEP GHRL
15 negative regulation of lipid storage GO:0010888 9.63 LEP CRP
16 acute-phase response GO:0006953 9.63 INS HP CRP
17 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.62 LEP INS IGF1 FSHR
18 bone mineralization involved in bone maturation GO:0035630 9.59 LEP IGF1
19 Sertoli cell proliferation GO:0060011 9.57 FSHR FSHB
20 positive regulation of corticotropin secretion GO:0051461 9.56 GHRL CRH
21 androgen catabolic process GO:0006710 9.55 SRD5A1 CYP19A1
22 cellular protein metabolic process GO:0044267 9.55 PRL INS IGFBP1 IGF1 BMP15
23 negative regulation of glucagon secretion GO:0070093 9.54 LEP CRH
24 female gonad development GO:0008585 9.54 FSHR CYP19A1 AMHR2
25 positive regulation of cortisol secretion GO:0051464 9.52 GHRL CRH
26 follicle-stimulating hormone signaling pathway GO:0042699 9.51 FSHR FSHB
27 positive regulation of cell proliferation GO:0008284 9.5 PRL LEP INS IGF1 FSHB CRH
28 diterpenoid metabolic process GO:0016101 9.49 SRD5A1 CRH
29 negative regulation of circadian sleep/wake cycle, REM sleep GO:0042322 9.43 GHRL CRH
30 female gamete generation GO:0007292 9.43 FSHR FSHB BMP15
31 positive regulation of steroid biosynthetic process GO:0010893 9.4 FSHB CGA
32 female pregnancy GO:0007565 9.02 PRL LEP GNRH1 FSHB CRH

Molecular functions related to Anovulation according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.28 PRL LEP INS IGF1 GNRH1 GHRL
2 follicle-stimulating hormone activity GO:0016913 8.96 FSHB CGA

Sources for Anovulation

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....